ATE451835T1 - Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae - Google Patents

Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Info

Publication number
ATE451835T1
ATE451835T1 AT00965349T AT00965349T ATE451835T1 AT E451835 T1 ATE451835 T1 AT E451835T1 AT 00965349 T AT00965349 T AT 00965349T AT 00965349 T AT00965349 T AT 00965349T AT E451835 T1 ATE451835 T1 AT E451835T1
Authority
AT
Austria
Prior art keywords
patient
compositions
viruses
protein
therapeutic methods
Prior art date
Application number
AT00965349T
Other languages
English (en)
Inventor
Stephen J Russell
Roberto Cattaneo
Kah-Whye Peng
Urs Schneider
Anthea L Murphy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE451835T1 publication Critical patent/ATE451835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00965349T 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae ATE451835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15587399P 1999-09-24 1999-09-24
PCT/US2000/026116 WO2001020989A1 (en) 1999-09-22 2000-09-22 Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family

Publications (1)

Publication Number Publication Date
ATE451835T1 true ATE451835T1 (de) 2010-01-15

Family

ID=22557120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965349T ATE451835T1 (de) 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Country Status (6)

Country Link
EP (1) EP1217891B1 (de)
AT (1) ATE451835T1 (de)
AU (1) AU7607900A (de)
CA (1) CA2383276A1 (de)
DE (1) DE60043547D1 (de)
WO (1) WO2001020989A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241617B2 (en) 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CN101054419A (zh) 2002-04-30 2007-10-17 株式会社载体研究所 具有修饰的蛋白酶依赖向性的载体
DE60334008D1 (de) 2002-05-03 2010-10-14 Mayo Foundation Reduzierter slam abhängiger zell eintritt
ES2565327T3 (es) 2003-01-14 2016-04-04 Dana Farber Cancer Institute Sensibilizador de terapia del cáncer
WO2004111249A2 (en) * 2003-06-13 2004-12-23 Polymun Scientific Immunbiologische Forschung Gmbh Protein constructs containing caspase recognition sites
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
WO2005049847A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
WO2005071085A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
NZ581958A (en) 2004-11-12 2011-01-28 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer
CA2598510C (en) 2005-02-18 2011-12-20 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
GB2463543A (en) * 2007-09-11 2010-03-24 Sapphire Energy Inc Molecule production by photosynthetic organisms
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
EP2085479A1 (de) * 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (de) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimäre newcastle-krankheitsviren und verwendungen davon
CN102917717B (zh) * 2010-06-10 2015-10-07 英特维特国际股份有限公司 抗肿瘤组合物
CN108977412A (zh) * 2012-01-26 2018-12-11 生命科技公司 用于提高病毒感染性的方法
KR20140128966A (ko) * 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 바이러스의 감염성을 증가시키는 방법
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
US10519426B2 (en) * 2013-09-03 2019-12-31 Medimmune Limited Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
WO2016110869A2 (en) * 2015-01-05 2016-07-14 Joshi Vishwas Dattatraya Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3063690A1 (en) 2017-05-16 2018-11-22 Mayo Foundation For Medical Education And Research Modified viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2230033C (en) * 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences

Also Published As

Publication number Publication date
WO2001020989A9 (en) 2002-10-03
EP1217891A1 (de) 2002-07-03
WO2001020989A1 (en) 2001-03-29
AU7607900A (en) 2001-04-24
CA2383276A1 (en) 2001-03-29
EP1217891B1 (de) 2009-12-16
EP1217891A4 (de) 2004-05-12
DE60043547D1 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
Sambhi et al. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
RU95115239A (ru) Аналог эритропоэтина
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
JP2014509197A (ja) 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
DE69836758D1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69627526D1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
CN105367661B (zh) 嵌合抗原受体及其基因和重组表达载体、工程化her1靶向性的nkt细胞及其应用
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
Ahmed et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery
CN105924526B (zh) 嵌合抗原受体及其基因和重组表达载体、carher1-nkt细胞及其制备方法和应用
CN105920592B (zh) Carher1-nkt细胞在制备用于治疗进展期her1阳性肺癌的制剂中的应用
Soehner et al. Oral induction of interferon by a low-molecular-weight compound

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties